Correspondence to Neuronal and Glial Metabolite Abnormalities in Participants with Persistent Neuropsychiatric Symptoms After COVID-19: A Brain Proton MRS Study

The Journal of Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 11, 2025

We were pleased to read the work of Drs.Ernst, et al. [1], who successfully conducted a proton magnetic resonance spectroscopy (MRS) study on participants with persistent neuropsychiatric symptoms after COVID-19.The reported lower metabolite concentrations: total N-acetylcompounds (tNAA; N-acetylaspartate + N-acetylaspartyl-glutamate) and glutamate glutamine (Glu Gln) in anterior cingulate cortex gray matter (ACC-GM) frontal white (FWM) post-COVID-19 group compared controls.Independent authors' study, we have investigated whether post-COVID fatigue relates bioenergetic dysfunction brain using MRS since 2022, reporting preliminary results May 2024 [2].While our target structure for measuring metabolic activity was posterior gyrus (PCG)-which is one most metabolically active regions also involved attention memory processesour overall settings similar, recruiting patients (Chalder

Language: Английский

---

Subphenotypes of Long COVID and the clinical applications of probiotics

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 183, P. 117855 - 117855

Published: Jan. 24, 2025

Language: Английский

---

Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA

Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 8

Published: Feb. 27, 2025

Nirmatrelvir/ritonavir, commonly known as Paxlovid, is one of the main drugs used to treat COVID-19. Neurological disorders are among adverse drug reactions (ADRs) linked yet comprehensive data-mining studies based on real-world neurological events induced by Paxlovid lacking. It an observational study, reduce risk bias affected COVID-19 disease, our study included only patients with disease. In this case, disproportionate analysis performed using Report Odds Ratio (ROR) and its 95% Confidence Interval (CI). We screened compared all medications associated (N = 439) found that 22 these were reactions. was a threefold greater number other combined 11,792), strong signal value (ROR 2.27). Compared COVID-19-related drugs, has highest stronger for neurologic-related Clinicians should pay special attention female taking within first 30 days, monitoring symptoms such dysgeusia, ageusia, headache, anosmia. addition, headache anosmia not uncommon occurrences mentioned in instructions be noted.

Language: Английский

---

High efficacy therapy to prevent the formation of meningeal tertiary lymphoid organs after CXCL13 index screening in early multiple sclerosis

Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19

Published: March 17, 2025

Postmortem studies have shown the presence of subpial inflammation with tertiary lymphoid organs (TLO) in meninges patients progressive multiple sclerosis, playing an important role pathophysiology disease. The chemokine (C-X-C motif) ligand 13 (CXCL13) induces formation these organs, thus promoting activity progression to disability sclerosis has been reduced, thanks effect disease modifying therapy. However, despite advances treatment immunomodulatory agents, we still lack specific laboratory biomarkers that could indicate state disease, either at time diagnosis or when escalation therapy seems be mandatory. In MRI not demonstrated TLO CNS, so far. determination CXCL13 index (ICXCL 13), clinical specimens, become a reliable biomarker for verification and TLO, contributing improving outcome, high efficacy therapy, setting.

Language: Английский

---

Neurofilament light chain as a biomarker for neurodegenerative changes in COVID-19 and clinical implications

Future Virology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: March 21, 2025

Language: Английский

---